Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $2.8 million.

  • Vivos Therapeutics' Cost of Revenue rose 8650.07% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year increase of 3759.43%. This contributed to the annual value of $6.0 million for FY2024, which is 871.61% up from last year.
  • Latest data reveals that Vivos Therapeutics reported Cost of Revenue of $2.8 million as of Q3 2025, which was up 8650.07% from $1.7 million recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Cost of Revenue high stood at $2.8 million for Q3 2025, and its period low was $860000.0 during Q1 2021.
  • In the last 5 years, Vivos Therapeutics' Cost of Revenue had a median value of $1.5 million in 2023 and averaged $1.5 million.
  • In the last 5 years, Vivos Therapeutics' Cost of Revenue surged by 17863.01% in 2021 and then plummeted by 2598.98% in 2023.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Cost of Revenue stood at $1.3 million in 2021, then grew by 18.91% to $1.6 million in 2022, then fell by 25.99% to $1.2 million in 2023, then surged by 38.14% to $1.6 million in 2024, then skyrocketed by 77.76% to $2.8 million in 2025.
  • Its Cost of Revenue was $2.8 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.5 million in Q1 2025.